Cargando…

A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer

The purpose of this prospective phase II clinical trial was to investigate the efficacy and safety of anlotinib in patients with relapsed small cell lung cancer (SCLC). Forty‐five patients with relapsed SCLC were enrolled and treated with anlotinib (one cycle of 12 mg daily for 14 days, discontinued...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Di, Nie, Jun, Hu, Weiheng, Dai, Ling, Zhang, Jie, Chen, Xiaoling, Ma, Xiangjuan, Tian, Guangming, Han, Jindi, Han, Sen, Long, Jieran, Wang, Yang, Zhang, Ziran, Fang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Cancer Therapy and Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689882/ https://www.ncbi.nlm.nih.gov/pubmed/32557583 http://dx.doi.org/10.1002/ijc.33161

Ejemplares similares

Salvage treatment with anlotinib for advanced non‐small cell lung cancer
por: Wu, Di, et al.
Publicado: (2019)

Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma
por: Wang, Yang, et al.
Publicado: (2018)

Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer
por: Chen, Meixia, et al.
Publicado: (2018)

Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China
por: Chen, Xiaoling, et al.
Publicado: (2021)

Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
por: Wang, Yang, et al.
Publicado: (2021)

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
por: Zhang, Jie, et al.
Publicado: (2021)

Prognostic factor analysis of patients with small cell lung cancer: Real‐world data from 988 patients
por: Ma, Xiangjuan, et al.
Publicado: (2021)

The overall survival benefit in Chinese ALK(+) NSCLC patients received targeted therapies
por: Tian, Guangming, et al.
Publicado: (2022)

Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102)
por: Nishikawa, Kazuhiro, et al.
Publicado: (2016)

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
por: Hu, Weiheng, et al.
Publicado: (2016)

Construction of an endoplasmic reticulum stress-related signature in lung adenocarcinoma by comprehensive bioinformatics analysis
por: Wang, Yang, et al.
Publicado: (2023)

A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastoma
por: Lewis, Elizabeth C., et al.
Publicado: (2020)

A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
por: Jo, Jung Hyun, et al.
Publicado: (2022)

Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study
por: Wang, Yang, et al.
Publicado: (2022)

Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial
por: Daniel, Davey, et al.
Publicado: (2021)

A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
por: Unseld, Matthias, et al.
Publicado: (2020)

Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study
por: Wu, Yi‐Long, et al.
Publicado: (2020)

Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study
por: Sun, Zimin, et al.
Publicado: (2018)

Evolving landscape and academic attitudes toward the controversies of global immuno‐oncology trials
por: Xu, Cheng, et al.
Publicado: (2021)

Real‐world outcomes of advanced melanoma patients not represented in phase III trials
por: van Zeijl, Michiel C. T., et al.
Publicado: (2020)

Molecular analysis of cell-free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancer
por: Zhang, Jie, et al.
Publicado: (2019)

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer
por: Hellmann, Matthew D., et al.
Publicado: (2020)

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
por: Weekes, Colin, et al.
Publicado: (2019)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Activation of WNT/β‐catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
por: Park, Ye‐Lim, et al.
Publicado: (2018)

Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study
por: Tannir, Nizar M., et al.
Publicado: (2021)

CRM197 reverses paclitaxel resistance by inhibiting the NAC‐1/Gadd45 pathway in paclitaxel‐resistant ovarian cancer cells
por: Tang, Xiao‐han, et al.
Publicado: (2019)

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
por: Eng, Cathy, et al.
Publicado: (2016)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial
por: Tesch, Hans, et al.
Publicado: (2018)

Special issue “The advance of solid tumor research in China”: Participants with a family history of cancer have a higher participation rate in low‐dose computed tomography for lung cancer screening
por: Guo, Lan‐Wei, et al.
Publicado: (2022)

Cross‐sectional survey of the impact of the COVID‐19 pandemic on cancer screening programs in selected low‐ and middle‐income countries: Study from the IARC COVID‐19 impact study group
por: Villain, Patricia, et al.
Publicado: (2021)

The role of neoadjuvant imatinib in gastrointestinal stromal tumor patients: 20 years of experience from a tertial referral center
por: Renberg, Sara, et al.
Publicado: (2022)

First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
por: Liu, Tianshu, et al.
Publicado: (2022)

Targeted therapy of the AKT kinase inhibits esophageal squamous cell carcinoma growth in vitro and in vivo
por: Liu, Xuejiao, et al.
Publicado: (2019)

Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers
por: Mondal, Susmita, et al.
Publicado: (2018)

Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models
por: Luo, Yong, et al.
Publicado: (2018)

Sorafenib with ASC‐J9(®) synergistically suppresses the HCC progression via altering the pSTAT3‐CCL2/Bcl2 signals
por: Xu, Junjie, et al.
Publicado: (2016)

Use of thermo‐coagulation as an alternative treatment modality in a ‘screen‐and‐treat’ programme of cervical screening in rural Malawi
por: Campbell, Christine, et al.
Publicado: (2016)

Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma
por: Wilkinson, Michelle J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ulolbol2n1jaklb3s398lg61s5